Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

High-Sensitivity MSD Assays for Cytokine Release Syndrome (CRS) Monitoring in CAR-T Cell Therapy Clinical Trials

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

High-Sensitivity MSD Assays for Cytokine Release Syndrome (CRS) Monitoring in CAR-T Cell Therapy Clinical Trials

High-Sensitivity MSD Assays for CRS Monitoring in CAR-T Therapies

CELL & GENE | RNA | BIOLOGICS

Monitoring Cytokine Release Syndrome (CRS) in CAR-T cell therapy clinical trials requires bioanalytical methods that offer superior sensitivity and multiplexing capabilities. Meso Scale Discovery (MSD) electrochemiluminescence immunoassays provide the wide dynamic range and low sample volume requirements necessary for precise quantification of key CRS-associated cytokines. This allows for robust safety profiling and informs clinical decision-making, directly supporting the development of safer and more effective cell therapies.

What is the primary advantage of MSD over standard ELISA for cytokine monitoring?
MSD technology offers significantly higher sensitivity and a much wider dynamic range compared to colorimetric ELISA. Its electrochemiluminescence detection method allows for the quantification of both low- and high-abundance cytokines within the same sample, while its multiplexing capability enables the simultaneous measurement of multiple analytes, conserving precious clinical sample volume.
Which cytokines are most relevant for a standard CRS panel?
A core CRS panel typically includes key pro-inflammatory and regulatory cytokines. The most frequently requested analytes are Interleukin-6 (IL-6), Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-10 (IL-10), Interleukin-2 (IL-2), and Granulocyte-macrophage colony-stimulating factor (GM-CSF). Custom panels can be developed to meet specific program needs.
How does sample matrix (e.g., serum vs. plasma) affect MSD assay performance?
While the platform is robust across different matrices, consistency is a requirement for clinical trial data integrity. We perform rigorous validation, including matrix effect assessments, to ensure that results from serum, plasma, or other matrices are accurate and reproducible. The choice of anticoagulant for plasma collection can also influence the stability of certain analytes.
What sample volume is required for a multiplex MSD panel?
A significant advantage of the MSD platform is its low sample volume requirement. Typically, only 25-50 µL of sample is needed per well, which is sufficient to run a multiplex panel measuring up to 10 distinct analytes. This is a considerable benefit when working with volume-limited samples from clinical trial participants.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

The Challenge of Cytokine Release Syndrome in Clinical Safety

The therapeutic success of CAR-T cell therapies is often accompanied by the risk of significant on-target, off-tumor toxicities, most notably Cytokine Release Syndrome. An excessive and uncontrolled release of pro-inflammatory cytokines can lead to severe clinical manifestations. Effective management of CRS depends on early detection and intervention, which requires highly sensitive and quantitative monitoring of the patient’s cytokine profile.

This bioanalytical challenge demands a platform capable of accurately measuring a dynamic range of cytokines that can shift by several orders of magnitude during a CRS event. The ability to profile multiple cytokines simultaneously from a single, small sample provides a more comprehensive view of the immune response.

Multiplexed Immunoassays for Comprehensive Cytokine Profiling

Meso Scale Discovery (MSD) immunoassays are purpose-built for the complexities of cytokine analysis in clinical settings. The platform’s electrochemiluminescence technology provides the analytical performance needed to support CAR-T therapy programs.

Feature Meso Scale Discovery (MSD) Traditional ELISA
Detection Method Electrochemiluminescence Colorimetric/Chemiluminescent
Dynamic Range 4-5 logs 2-3 logs
Sensitivity Sub-pg/mL pg/mL to ng/mL
Multiplexing Up to 10 analytes per well Single analyte per well
Sample Volume ~25 µL ~100 µL

MAKING LIFE-SAVING RESEARCH AFFORDABLE

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Correlating Immunogenicity with Therapeutic Response

Understanding patient-specific immune responses is fundamental to interpreting safety and efficacy data. The factors driving immune reactions can be highly individualized. For instance, studies in AAV-mediated gene therapy have shown how patient-specific genetics, such as a rare HLA allele, can dictate the nature of a T-cell response and consequently impact transgene expression (PMID: 28137880).

This principle extends to cell therapies. A patient’s unique cytokine signature during a CRS event is a significant biomarker for both safety and therapeutic activity. By precisely quantifying this response, we can better correlate immunodynamics with clinical outcomes.

Franklin Biolabs GxP Bioanalytical Capabilities

Our bioanalytical laboratory, operating within a >100,000 sq ft facility, provides GxP-compliant assay development, validation, and sample analysis to support programs from preclinical research through pivotal clinical trials. Through our strategic partnerships with leading technology providers, we deliver robust data packages that support an average 18-24 month IND timeline. Since 2019, programs supported by our scientific leadership have achieved a 100% IND success rate, with the Franklin Biolabs brand formally launching in 2024 to expand these specialized services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities